Alzheimer's Disease Viewed as a Neurovascular Inflammatory Disorder

阿尔茨海默病被视为一种神经血管炎症性疾病 项目摘要/摘要 阿尔茨海默病是一种毁灭性的神经退行性疾病，缺乏有效的治疗方法。多数 检验长期存在的阿尔茨海默病淀粉样蛋白假说的临床试验显示前景渺茫。小说的未来 针对该病其他病理生理过程的治疗尚不确定。越来越多的证据 支持神经血管炎症作为AD发病和加重的主要原因或加重因素的作用 进步。然而，科学界还没有给AD贴上血管疾病的标签，问题仍然存在 关于神经血管炎症作为潜在治疗靶点的可行性。为了解决这一争议 迎头赶上，纽约科学院将举办为期一天的研讨会并同时转播网络研讨会， “阿尔茨海默病被视为一种神经血管炎症性疾病”，2016年12月6日。这样做的目的是 研讨会的目的是评估临床和临床前数据，调查神经血管病理学在 AD的发展。理解如何在临床上检验基于血管的假说的关键障碍 将讨论AD的治疗，包括监测疾病进展的最新成像进展。 此外，关于分子和生理过程的新兴科学可以被用作 将介绍新的治疗方法。这次研讨会将填补会议格局中的一个重要空白， 对AD和血管疾病研究之间的协同作用进行有重点的、深入的讨论， 建立在最近确定的需要的基础上，更好地了解AD和血管的神经血管失调 痴呆(36例)。这一里程碑式的活动将团结200名面对面的基础、翻译和临床研究人员- 以及来自学术界、工业界、政府和非营利组织的全球网络研讨会参与者 致力于神经退行性疾病和血管疾病的组织，以努力了解， 预防和治疗AD和血管性痴呆，如小血管疾病(SVD)。会议将解决 5个中心目标：(1)阐明遗传信息与阿尔茨海默病神经血管病理的关系 和SVD；(Ii)探索对血管功能和中枢神经系统至关重要的新的分子靶点和生理过程 健康，使用人体研究和动物模型；(3)描述神经血管失调的临床方面 AD和SVD中的炎症和识别血管机制的生物标志物；(Iv)识别 在预防和治疗阿尔茨海默病方面取得突破所需的知识差距和未来研究；以及(五) 展示和鼓励早期职业、女性和代表性不足的少数群体的参与 调查人员通过简短的谈话、海报介绍和奖品、旅行奖学金和折扣登记。 此外，还将通过联播网络研讨会实现NINDS传播信息的具体目标 并出版了一本经久不衰的开放获取学院eBriefing。协作、多学科 对于满足AD患者未得到满足的紧急需求，方法将是至关重要的。为此，本次活动将 从广泛的角度考虑AD的新的疾病机制和治疗目标。

Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder PROJECT SUMMARY / ABSTRACT Alzheimer’s disease (AD) is a devastating neurodegenerative disorder lacking effective treatments. Most clinical trials testing the long-standing amyloid hypothesis of AD have shown little promise. The future of novel treatments targeting other pathophysiological processes in the disease is uncertain. Growing evidence supports a role for neurovascular inflammation as a major causative or exacerbating factor in AD onset and progression. However, the scientific community has yet to label AD a vascular disease and questions remain about the viability of neurovascular inflammation as a potential therapeutic target. To address this controversy head-on, the New York Academy of Sciences will present a 1-day symposium and simulcast Webinar, “Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder” on 12/6/2016. The goal of this symposium is to evaluate clinical and preclinical data investigating the role of neurovascular pathology in the development of AD. Critical barriers to understanding how to clinically test vascular-based hypotheses for the treatment of AD will be discussed, including recent imaging advances for monitoring disease progression. Moreover, emerging science on molecular and physiological processes that can be leveraged as targets for novel therapeutics will be presented. This symposium will fill an important gap in the conference landscape, presenting a focused, in-depth discussion on the synergies between AD and vascular disease research, building upon the recently defined need to better understand neurovascular dysregulation in AD and vascular dementia (36). This landmark event will unite 200 in-person basic, translational, and clinical researchers — along with a global audience of Webinar participants — from academia, industry, government, and non-profit organizations, working on neurodegenerative disorders and vascular disease in an effort to understand, prevent, and treat AD and vascular dementias such as small vessel disease (SVD). Sessions will address 5 central aims: (i) Elucidate the relationship between genetic information and neurovascular pathology in AD and SVD; (ii) Explore novel molecular targets and physiological processes critical to vascular function and CNS health, using human studies and animal models; (iii) Describe clinical aspects of neurovascular dysregulation and inflammation in AD and SVD and identify biomarkers for vascular-based mechanisms; (iv) Identify knowledge gaps and future research required for breakthroughs in prevention and treatment of AD; and (v) Showcase and encourage the participation of Early-Career, female, and Underrepresented Minority investigators via short talks, poster presentations and prizes, travel fellowships, and discounted registration. In addition, the NINDS’ specific goal of disseminating information will be met through a simulcast Webinar and publication of an enduring open-access Academy eBriefing. A collaborative, multidisciplinary approach will be critical to meeting the urgent unmet need for AD patients. To that end, this event will consider new disease mechanisms and therapeutic targets for AD, from a broad range of perspectives.